Cowen Starts Unum Therapeutics (UMRX) at Market Perform

Cowen initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Market Perform rating.

Analyst Eric Schmidt comments "Relative to 1st-gen T cell therapies, Unum’s Antibody-Coupled T cell Receptor (ACTR) platform seeks to provide a universal approach with the potential for greater tunability. While lead candidate ACTR087 + Rituxan has activity, we await more data on the profile of this and other ACTR combos before recommending shares."

For an analyst ratings summary and ratings history on Unum Therapeutics click here. For more ratings news on Unum Therapeutics click here.

Shares of Unum Therapeutics closed at $11.98 Friday.

You May Also Be Interested In

• Marvell (MRVL) PT Raised to $225 at TD Cowen
• Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets
• TD Cowen Starts Freenome Inc. (FRNM) at Buy